Bicycle Therapeutics Pivots, Cuts Workforce Amid Nuzefatide Progress
Event summary
- Bicycle Therapeutics reported Q1 2026 revenue of $0.9 million, down from $10.0 million in Q1 2025, due to terminated collaborations.
- The company is initiating a workforce reduction of approximately 30%, anticipating $50 million in annual savings.
- Phase 1/2 data for nuzefatide pevedotin in combination with nivolumab showed a 40% ORR in EphA2+ mUC patients.
- Bicycle Therapeutics is converting the Duravelo-2 trial to a randomized Phase 2 trial and prioritizing nuzefatide and radiotherapeutics.
- The company now projects a cash runway extending into 2030 following the restructuring.
The big picture
Bicycle Therapeutics' strategic pivot reflects a broader trend in the biotech sector, where companies are increasingly forced to prioritize pipelines and cut costs amid market volatility. The company's focus on nuzefatide, a potentially first-in-class EphA2 targeting drug conjugate, represents a high-risk, high-reward bet on a historically undruggable target. The company's ability to demonstrate clinical efficacy and secure regulatory approval will be crucial for its long-term viability.
What we're watching
- Clinical Efficacy
- The success of the Phase 2 trial for nuzefatide in pancreatic cancer will be critical in validating the drug's potential and justifying further investment, given the historical difficulty in targeting EphA2.
- Financial Stability
- Whether the cost savings from the workforce reduction and strategic shift will be sufficient to sustain operations until potential future revenue streams materialize remains a key risk.
- Regulatory Path
- The feedback from regulatory agencies regarding the development path for zelenectide will dictate whether Bicycle Therapeutics can leverage the promising early data or must abandon the program.
Related topics